STOCK TITAN

Capricor Therapeutics Inc - $CAPR STOCK NEWS

Welcome to our dedicated page for Capricor Therapeutics news (Ticker: $CAPR), a resource for investors and traders seeking the latest updates and insights on Capricor Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Capricor Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Capricor Therapeutics's position in the market.

Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) will release its financial results for the third quarter ended September 30, 2023, after the market close on Tuesday, November 14, 2023, and will host a webcast and conference call at 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
-
Rhea-AI Summary
Capricor Therapeutics to host webinar with Parent Project Muscular Dystrophy to discuss clinical trial of CAP-1002 for treating Duchenne muscular dystrophy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.85%
Tags
conferences
-
Rhea-AI Summary
Capricor Therapeutics announces positive data supporting CAP-1002's efficacy in treating Duchenne Muscular Dystrophy and potential of StealthX™ technology for ASO delivery
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.52%
Tags
none
Rhea-AI Summary
Capricor Therapeutics announces definitive agreements for the issuance and sale of 4,935,621 shares of common stock in a registered direct offering with an expected gross proceeds of approximately $23 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.24%
Tags
-
Rhea-AI Summary
Capricor Therapeutics receives positive FDA feedback on trial design and timeline for CAP-1002 in treating DMD, confirming path towards BLA submission. Company on track to complete HOPE-3 enrollment and report interim analysis in Q4 2023. Plans to submit BLA in 2025. Topline data expected in Q4 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-41.24%
Tags
none
-
Rhea-AI Summary
Capricor Therapeutics appoints Michael Kelliher to its Board of Directors
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.3%
Tags
management
Rhea-AI Summary
Capricor Therapeutics presented positive two-year data from their HOPE-2 open label extension study for CAP-1002 in patients with Duchenne Muscular Dystrophy (DMD). The results showed evidence of skeletal and cardiac functional improvements, supporting the potential long-term benefit of CAP-1002 treatment. They also held a clinical meeting with the FDA to discuss the results and the pathway towards a potential Biologics License Application (BLA) submission. Enrollment in their Phase 3 HOPE-3 trial is progressing well, with plans to complete enrollment and report interim analysis in Q4 2023. Capricor plans to submit data from the ongoing HOPE-2-OLE study at a medical meeting in Q4 2023. They completed construction of their San Diego GMP manufacturing facility and plan to have commercial-scale GMP CAP-1002 clinical doses available in Q3 2023. Capricor's cash position as of June 30, 2023, was approximately $37.8 million. They believe their available cash will be sufficient to cover expenses and capital requirements through Q3 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
21.66%
Tags
-
Rhea-AI Summary
Capricor Therapeutics (NASDAQ: CAPR) will release its financial results for the second quarter ended June 30, 2023, after the market close on August 7, 2023. A webcast and conference call will be hosted at 4:30 p.m. ET on the same day.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.45%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.66%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Capricor Therapeutics Inc

Nasdaq:CAPR

CAPR Rankings

CAPR Stock Data

172.32M
26.04M
8.2%
21.62%
11.12%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
BEVERLY HILLS

About CAPR

capricor therapeutics, inc. (nasdaq: capr) is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. our innovative technology builds upon a large body of scientific research and enables us to approach the treatment of diseases in novel ways. capricor’s lead candidate, cap-1002, is an “off-the-shelf” cardiac cell therapy that is currently in clinical development for the treatment of duchenne muscular dystrophy (dmd). cap-1002 consists of allogeneic cardiosphere-derived cells, or cdcs, a unique population of cells which include progenitor cells that have been shown to exert potent immunomodulatory activity, which alters the immune system’s activity to stimulate cellular regeneration. cdcs have been the subject of over 100 peer-reviewed scientific publications and have been administered to approximately 140 human subjects across several clinical trials. capricor has